{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:27:53Z","timestamp":1787149673705,"version":"build-2736575974"},"reference-count":18,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1136\/ejhpharm-2025-004740","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:10:22Z","timestamp":1765869022000},"page":"431-436","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of impact of clinical variables on enoxaparin dosing and anti-Xa factor concentration"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3475-3736","authenticated-orcid":false,"given":"Arnau","family":"Torrent-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Pharmacy Service, Department of Medicines, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-8107","authenticated-orcid":false,"given":"Carla","family":"Bastida","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Department of Medicines, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8128-345X","authenticated-orcid":false,"given":"Dolors","family":"Soy-Muner","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Department of Medicines, Hospital Clinic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026081906551078000_33.5.431.1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301"},{"key":"2026081906551078000_33.5.431.2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11239-019-01920-y","article-title":"Description of anti-Xa monitoring practices during low molecular weight heparin use","volume":"48","author":"Lin","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2026081906551078000_33.5.431.3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.36518\/2689-0216.1464","article-title":"Anti-Factor Xa Level Monitoring for Enoxaparin Prophylaxis and Treatment in High-Risk Patient Groups","volume":"4","author":"Sikes","year":"2023","journal-title":"HCA Healthc J Med"},{"key":"2026081906551078000_33.5.431.4","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2009.164"},{"key":"2026081906551078000_33.5.431.5","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/126975","article-title":"Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis","volume":"2015","author":"Yentz","year":"2015","journal-title":"Thrombosis"},{"key":"2026081906551078000_33.5.431.6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1310\/hpj5203-214","article-title":"Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?","volume":"52","author":"Kufel","year":"2017","journal-title":"Hosp Pharm"},{"key":"2026081906551078000_33.5.431.7","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2008.08.005","article-title":"Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency","volume":"123 Suppl 1","author":"Clark","year":"2008","journal-title":"Thromb Res"},{"key":"2026081906551078000_33.5.431.8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-9-200605020-00011"},{"key":"2026081906551078000_33.5.431.9","unstructured":"Weir CB , Jan A . BMI Classification Percentile And Cut Off Points. Treasure Island: StatPearls, 2025."},{"key":"2026081906551078000_33.5.431.10","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2023.10.018"},{"key":"2026081906551078000_33.5.431.11","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"2026081906551078000_33.5.431.12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22222"},{"key":"2026081906551078000_33.5.431.13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024893"},{"key":"2026081906551078000_33.5.431.14","doi-asserted-by":"publisher","DOI":"10.1177\/1076029614568713"},{"key":"2026081906551078000_33.5.431.15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4212\/cjhp.v68i1.1423","article-title":"Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review","volume":"68","author":"Egan","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"2026081906551078000_33.5.431.16","first-page":"63","article-title":"Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications","volume":"10","author":"Tahaineh","year":"2018","journal-title":"Clin Pharmacol"},{"key":"2026081906551078000_33.5.431.17","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003253420"},{"key":"2026081906551078000_33.5.431.18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00228-023-03558-5","article-title":"The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients","volume":"79","author":"Mast","year":"2023","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:55:41Z","timestamp":1787147741000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/ejhpharm-2025-004740"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004740","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}